Similar articles

Abstract: Objective: To evaluate the immunological effects of three types of domestic 10-µg/dose hepatitis B vaccines in adults compared with a foreign vaccine, and to provide scientific evidence in support of adult hepatitis B vaccination. Methods: Adults from five counties (Deqing, Changxing, Nanxun, Wuxing, Anji) in Huzhou City, Shaoxing County and Tongxiang County, Zhejiang Province, China were selected. Blood samples were taken to assess serum HBsAg, anti-HBs, and anti-HBc using a chemiluminescence immunoassay. Adults, aged 16 to 49 years and who were anti-HBs negative at baseline, received hepatitis B immunizations at 0, 1, and 6 months. Anti-HBs levels were assessed one month after the third and final vaccination. Results: A total of 1872 adults were immunized and the average positive rate was 89.5%. Four types of hepatitis B vaccine were used, including three from Chinese companies (Shenzhen Kangtai, Dalian High-Tech, and North China Pharmaceutical) and one from a UK company (GlaxoSmithKline). Their seroconversion rates were 81.67%, 95.05%, 89.64%, and 86.81%, respectively. There was a significant difference between the anti-HBs positive conversion rates of the four types (P<0.005) but the seroconversion rates among the different vaccines were not significantly different (χ²=2.123, P=0.145). The average anti-HBs geometric mean titers (GMTs) of non-immune adults immunized with each of the four vaccines were 177.28, 473.23, 246.13, and 332.20 mIU/ml, respectively. There were no statistically significant differences in the GMTs between the three types of domestic vaccine and the foreign vaccine (t=−1.575, P=0.116). Conclusions: Domestic recombinant hepatitis B vaccines can achieve immunization effects comparable to those of a foreign vaccine.

[1]Bonanni, P., 1995. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine, 13(s1):68-71.

[2]Bryan, J.P., Craig, P.G., Reyes, L., Hakre, S., Jaramillo, R., Harlan, H., MacArthy, P., Legters, L.J., 1995. Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines. Vaccine, 13(11):978-982.

[3]Chang, M.H., Hadzic, D., Rouassant, S.H., Jonas, M., Kohn, I.J., Negro, F., Roberts, E., Sibal, A., 2004. Acute and chronic hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr., 39(s2):584-588.

[4]Coates, T., Wilson, R., Patrick, G., Andre, F., Watson, V., 2001. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther., 23(3):392-403.

[5]Daniels, D., Grytdal, S., Wasley, A., 2009. Surveillance for acute viral hepatitis―United States, 2007. MMWR Surveill. Summ., 58(3):1-27.

[6]Dong, M.H., Lin, Y.D., Qian, Y.H., Jiang, Y., Deng, Y., Ding, S., Ren, Y.J., 2009. Immunity effect of homemade recombinant yeast-derived hepatitis B vaccine in adults. Mod. Med. J. China, 11(2):24-26.

[7]Ganczak, M., Szych, Z., Korzen, M., 2009. Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: a cross-sectional study. Vaccine, 27(30):3969-3974.

[8]Ganem, D., Prince, A.M., 2004. Hepatitis B virus infection―natural history and clinical consequences. N. Engl. J. Med., 350(11):1118-1129.

[9]Gilbert, C.L., Klopfer, S.O., Martin, J.C., Schodel, F.P., Bhuyan, P.K., 2011. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum. Vaccin, 7(12):1336-1342.

[10]Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., Margolis, H.S., 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol., 34(6):1329-1339.

[11]Gong, X.Y., Zhong, J.Y., 2009. Evaluation of Immunogenicity of 10 µg Recombinant yeast-derived hepatitis B vaccine in adults. China Prevent Med., 10(10):934-936 (in Chinese).

[12]Jilg, W., Schmidt, M., Deinhardt, F., 1988. Persistence of specific antibodies after hepatitis B vaccination. J. Hepatol., 6(2):201-207.

[13]Lavanchy, D., 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat., 11(2):97-107.

[14]Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., Zhang, Y., Liu, J., Gong, X., Chen, Y., et al., 2009a. Epidemiological serosurvey of hepatitis B in China― declining HBV prevalence due to hepatitis B vaccination. Vaccine, 27(47):6550-6557.

[15]Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., Zhang, Y., Liu, J., Gong, X., Chen, Y., et al., 2009b. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J. Infect. Dis., 200(1):39-47.

[16]Lu, F.M., Zhuang, H., 2009. Management of hepatitis B in China. Chin. Med. J. (Engl.), 122(1):3-4.

[17]Mast, E.E., Mahoney, F.J., Alter, M.J., Margolis, H.S., 1998. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine, 16(Suppl.):48-51.

[18]Mast, E.E., Weinbaum, C.M., Fiore, A.E., Alter, M.J., Bell, B.P., Finelli, L., Rodewald, L.E., Douglas, J.M.Jr., Janssen, R.S., Ward, J.W., 2006. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm. Rep., 55(RR-16):1-33, quiz CE31-CE34.

[19]Rendi-Wagner, P., Kundi, M., Stemberger, H., Wiedermann, G., Holzmann, H., Hofer, M., Wiesinger, K., Kollaritsch, H., 2001. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine, 19(15-16):2055-2060.

[20]Shen, L.Z., Yao, J., 2011. Study development on booster immune strategy of hepatitis B vaccine. Zhejiang J. Prevent. Med., 23(12):22-25 (in Chinese).

[21]Trivello, R., Chiaramonte, M., Ngatchu, T., Baldo, V., Majori, S., Moschen, M.E., Simoncello, I., Renzulli, G., Naccarato, R., 1995. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine, 13(2):139-141.

[22]Weinbaum, C.M., Williams, I., Mast, E.E., Wang, S.A., Finelli, L., Wasley, A., Neitzel, S.M., Ward, J.W., 2008. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep., 57(RR-8):1-20.

[23]WHO (World Health Organization), 2000. Hepatitis B. WHO, Geneva, Switzerland. Available from http://www.who.int/mediacentre/factsheets/fs204/en [Accessed on 2 June 2010].

[24]Yao, J., Chen, Y.D., 2009. Immunity effect of domestic hepatitis B vaccine in adults. China Prevent Med., 10(4):258-261 (in Chinese).

[25]Yao, J., Ren, J.J., Shen, L.Z., Chen, Y.D., Liang, X.F., Cui, F.Q., Li, Q., Jiang, Z.G., Wang, F.Z., 2011. The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11–15 years after primary vaccination. Hum. Vaccin., 7(10):1055-1059.

[26]Young, M.D., Gooch, W.M.3rd, Zuckerman, A.J., Du, W., Dickson, B., Maddrey, W.C., 2001. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination. J. Med. Virol., 64(3):290-298.

[27]Yuan, Y.B., Zheng, X.H., Wang, Z.Q., 2003. Study on the immuno-effects and security of Chinese Hamster Ovary (CHO) cell hepatitis B vaccine among adults, under different dosages. Chin. J. Infect. Dis., 21(6):423-424 (in Chinese).

[28]Zhang, W., Lin, C., Han, L., Li, L., Gao, P., Lin, H., Gong, X., Huang, F., Tang, Y., Ma, J., 2010. Study on the immuno-effects and influencing factors of Chinese Hamster Ovary (CHO) cell hepatitis B vaccine among adults, under different dosages. Chin. J. Epidemiol., 31(7):767 (in Chinese).

[29]Zuckerman, J., Langer, B., 2005. Hepatitis B vaccination in a school age population: a feasibility study. J. Med. Virol., 76(1):47-54.